In her 29 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
She is one of six Managing Partners serving on the firm’s Investment Committee, which managed seven venture capital funds and one public fund for life sciences investing in US and Europe. Kate is responsible for biotech investments which include investments in small-molecule drug discovery and development projects, biotherapeutic development projects, and drug discovery platforms in a broad range of clinical areas.
In May 2020 Kate was appointed Chair of the UK Vaccine Taskforce reporting to the Prime Minster to lead UK efforts to find and manufacture a COVID-19 vaccine on a six month engagement stepping down as Chair in December 2020. On December 8th 2020 the UK started COVID-19 vaccinations – the first Western country to do so.